4.6 Article

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

期刊

ALZHEIMERS RESEARCH & THERAPY
卷 11, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s13195-019-0470-7

关键词

Biomarkers; Frontotemporal dementia; Tau imaging; Neuropathology; Tau

资金

  1. National Institute on Aging [K23AG055688, K23AG045289, K08AG052648, K24AG053435, P01 AG019724, U01 AG052943, P50-AG023501, R01AG034570, R01AG038791]
  2. Fondation pour la Recherche Medicale
  3. Alzheimer's Association [AARF-16-443577]
  4. UCSF-ADRC
  5. UCSF PPG
  6. John Douglas French Alzheimer's Foundation
  7. National Institute of Neurological Disorders and Stroke [R01 NS050915, U54NS092089]
  8. National Institute on Deafness and Other Communication Disorders [K24 DC015544]
  9. State of California Department of Health Services Alzheimer's Disease Research Center of California [DHS04-35516, 04-33516]
  10. Consortium for Frontotemporal Dementia Research
  11. Bluefield Project to Cure FTD
  12. Association for Frontotemporal Degeneration
  13. Michael J. Fox Foundation
  14. Tau Consortium

向作者/读者索取更多资源

BackgroundThe tau positron emission tomography (PET) ligand F-18-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer's disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain.MethodsWe performed F-18-flortaucipir imaging in patients with the FTD syndromes (n=45): nonfluent variant primary progressive aphasia (nfvPPA) (n=11), corticobasal syndrome (CBS) (n=10), behavioral variant frontotemporal dementia (bvFTD) (n=10), semantic variant primary progressive aphasia (svPPA) (n=2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau (MAPT) (n=6), chromosome 9 open reading frame 72 (C9ORF72) (n=5), and progranulin (GRN) (n=1). All patients underwent MRI and -amyloid biomarker testing via C-11-PiB or cerebrospinal fluid. F-18-flortaucipir uptake in patients was compared to 53 -amyloid negative normal controls using voxelwise and pre-specified region of interest approaches.ResultsOn qualitative assessment, patients with nfvPPA showed elevated F-18-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of -amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated F-18-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer's-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild F-18-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology.Conclusions(18)F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据